bioMerieux
BIM.PA Mid CapHealthcare · Diagnostics & Research
Mis à jour: Aug 2, 2026, 22:14 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
bioMerieux en bref
bioMerieux (BIM.PA) is currently trading at 69,10 € with a market capitalization of 7,1 Md €. The trailing P/E ratio stands at 17.72x, with a forward P/E of 14.81x. The 52-week range spans from 65,60 € to 128,30 €; the current price is 46.1% below the yearly high. Year-over-year revenue growth stands at -3.9%. The net profit margin stands at 11.59%.
💰 Dividende
bioMerieux pays an annual dividend of 0,98 € per share, representing a yield of 1.42%. The payout ratio stands at 25.13%.
📊 Avis des analystes
14 analystes évaluent bioMerieux (BIM.PA) au consensus : Conserver. L'objectif de cours moyen est de 79,04 €, soit un potentiel de +14.39% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 64,00 € à 100,00 €.
bioMerieux : la thèse d'investissement en détail
bioMerieux (BIM.PA) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in France. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Earnings growth of 41.9% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. The combination of a 56.13% gross margin and 15.23% operating margin shows the business converts revenue into profit efficiently — a hallmark of competitive moat.
Le scénario baissier
Revenue is contracting at -3.9% year-over-year — until that trend reverses, valuation is exposed to further downgrades.
Valorisation en contexte
The EV/EBITDA multiple of 7.47x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.
À surveiller
- The forward P/E of 14.81x is meaningfully below the trailing 17.72x — analysts expect earnings to step up; the next earnings release is the test.
- The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
Thèse d'investissement : forces et faiblesses
- Marge brute élevée de 56.13% — signe d'un pouvoir de fixation des prix
- Bilan solide avec faible endettement (D/E 9.81)
- Free cash flow positif
- –CA en contraction (-3.9% sur un an)
Aperçu technique
Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).
Profil de risque
The data points to relatively defensive market behavior.
Trading Data
💵 Dividend Info
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy bioMerieux?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Plutôt un fonds qu’une action isolée ? Comparatif d’ETF :
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news